HNF HAS COME UP WITH TEN WAYS YOU CAN DO YOUR PART AND HELP ALL OF US SPREAD CHARCOT-MARIE-TOOTH AWARENESS:
HNF sees great opportunity in partnering with NORD to fill the research gaps that can lead to a better understanding of how these rare diseases progress over time.
a drug candidate has reached Phase 3 clinical trial, the critical last phase before potential FDA market approval
We wanted to learn more about essential oils and how they can be used to help manage the symptoms of the CMT patient, so we reached out to Sarah Miller, a Wellness Advocate with doTERRA essential oils.
Kassandra generously shared the story of their friendship with us: I met Molly while living abroad in Tel Aviv, Israel. She just moved there and reached out to me to write for a foodie website I was running at the time.
The Hereditary Neuropathy Foundation Announces New Partnership With Acetylon Pharmaceuticals To Explore Potential Therapies For Charcot-Marie-Tooth Disease
The Hereditary Neuropathy Foundation (HNF) is proud to announce a new partnership with Acetylon Pharmaceuticals, Inc., a leader in the development of selective histone deacetylase (HDAC) inhibitors for enhanced therapeutic outcomes.
Hot Topic In HNF’s Inspire Online Support And Discussion Community: Hearing Loss And Charcot-Marie-Tooth
Our shared stories help show a connection between CMT and the symptoms we experience, such as hearing loss.
HNF gets answers to questions on what is genetic testing, cost, family history, what happens to the data.
HNF is proud to report that over $36,000 was raised for research for CMT2A at this annual event!